No Data
Junshengtai Pharmaceutical (02511) rose 11% in the afternoon, and plans to establish a production raw material operating entity base in Hebei Cangzhou.
Jingu finance news | Junshengtai Medicine (02511) surged in the afternoon, with a report of HKD 1.29, up 11.21%, and a turnover of HKD 29.3397 million as of press time. On the news side, the company previously announced that, after negotiating with relevant local government departments, the group decided to establish a production raw material operation main base in Nan Dagang Industrial Park, Bohai New Area, Cangzhou City, Hebei Province, hoping to take full advantage of local preferential policies and establish and improve the group's raw material production and supply capacity at a relatively optimal cost, and establish a reliable strategic cooperation and partner relationship for the group's core products in China. Currently, it is actively communicating with the local government and interests.
Kunshengtai Medicine-B (02511): It has decided to establish a production raw material operation main base in Nandagang Industrial Park of Bohai New District, Cangzhou, Hebei Province.
Junshengtai pharmaceutical-B (02511) announced that after consultation with relevant regional government departments, the group has decided to establish a production raw material operation main base in Nandagang industrial park, Bohai New Area, Cangzhou, Hebei Province. Through business expansion plans, the group expects to fully utilize local preferential policies and establish and enhance the group's raw material production and supply capabilities at a relatively lower cost, in order to establish reliable strategic cooperation and partnership for the group's core products in China. The company believes that the above business expansion plan is in line with the overall interests of the company and its shareholders.
Express News | HighTide Therapeutics Inc - Actively Communicating With Local Authorities and Stakeholders on Business Expansion Plan
Statistics on unusual proportion of SmartHK Connect on June 28th.
Abnormal statistical proportion of ChiNext Stock Connect on June 27th, 2024.
Patient enrollment has been completed for the Phase III clinical trial of HTD1801 for the treatment of type II diabetes by KunShengTai Pharmaceutical-B (02511.HK).
On June 27th, Healthcare International-B (02511.HK) announced that the company's self-developed intestinal and hepatic anti-inflammatory and metabolic regulator HTD1801 (berberine dihydrochloride) has completed patient enrollment for 2 Phase III clinical registration trials for type 2 diabetes (T2DM) patients. The two Phase III registration trials are as follows: HTD1801.PCT105: A multicenter, randomized, double-blind, placebo-controlled study (SYMPHONY-1) evaluating the efficacy and safety of HTD1801 in type 2 diabetes patients with poor blood glucose control after dietary and exercise interventions.
Statistics of abnormal proportion of Stock Connect of China Tong in Zhixun|June 27.
Abnormal statistics of Smart Hong Kong Stock Connect Proportion | 26th June 2024
No Data
